Immutep Ltd has released a press release.
Fast Track granted by US FDA for Efti in 1st line NSCLC
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Immutep
- Immutep Receives A$2.7 million R&D French Tax Incentive
- Clinical Development Update for Eftilagimod Alpha
- New investigator-initiated ph2 trial in Soft Tissue Sarcoma
- Appendix 4E & 2022 Full Year Statutory Accounts
- Japanese Patent Grant for efti, soluble LAG-3 with anti-PD-1
Later from Immutep
- Abstracts accepted for Presentation at SITC 2022
- Independent DMC recommends to continue TACTI-003 as planned
- Late Breaking Abstract accepted for SITC Oral Presentation
- New Patents Granted in Japan and South Korea for Efti
- Immutep Webcast to discuss clinical data presented at SITC
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep